Vija Klusa

Prof. Vija Klusa


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Pharmacological Research
Verified
Journal Article
Closed access
VKVija Klusa
Vija Klusa

14 May 2020 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
KNKarīna Narbute
Karīna Narbute
VPVladimirs Pilipenko
Vladimirs Pilipenko
JPJolanta Pupure
Jolanta Pupure
TKToms Klinovičs
Toms Klinovičs
JAJānis Auders
Jānis Auders
VKVija Klusa
Vija Klusa

Verified
Journal Article
Open access
PDF file
VKVija Klusa
Vija Klusa
SISergejs Isajevs
Sergejs Isajevs
DSDarja Svirina
Darja Svirina
JPJolanta Pupure
Jolanta Pupure
UBUlrika Beitnere
Ulrika Beitnere
HVHarry V. Vinters
Harry V. Vinters
Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) that was generated via a unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6‑OHDA). We assessed the expression of cell biomarkers that are involved in signaling cascades and provide neural and glial integration: the neuronal marker TH (tyrosine hydroxylase); ubiquitin (a regulatory peptide involved in the ubiquitin-proteasome degradation system); Notch-3 (a marker of progenitor cells); IBA-1 (a marker of microglial cells); glial fibrillary acidic protein, GFAP (a marker of astrocytes); and inducible nitric oxide synthase, iNOS (a marker of inflammation). The data show that in the 6-OHDA-lesioned striatum, mildronate completely prevented the loss of TH, stimulated Notch-3 expression and decreased the expression of ubiquitin, GFAP and iNOS. These results provide evidence for the ability of mildronate to control the expression of an array of cellular proteins and, thus, impart multi-faceted homeostatic mechanisms in neurons and glial cells in a rat model of PD. We suggest that the use of mildronate provides a protective effect during the early stages of PD that can delay or halt the progression of this neurodegenerative disease.

1 May 2013 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
VKVija Klusa
Vija Klusa
RMRuta Muceniece
Ruta Muceniece
SISergejs Isajevs
Sergejs Isajevs
DIDarja Isajeva
Darja Isajeva
UBUlrika Beitnere
Ulrika Beitnere
HVHarry V. Vinters
Harry V. Vinters

11 July 2006 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
LKLinda Klimaviciusa
Linda Klimaviciusa
VKVija Klusa
Vija Klusa
GDGunars Duburs
Gunars Duburs
AKAllen Kaasik
Allen Kaasik
AKAnti Kalda
Anti Kalda
AZAlexander Zharkovsky
Alexander Zharkovsky

1 July 2013 in Medicina
Verified
Journal Article
Open access
VKVija Klusa
Vija Klusa
UBUlrika Beitnere
Ulrika Beitnere
JPJolanta Pupure
Jolanta Pupure
SISergejs Isajevs
Sergejs Isajevs
JRJuris Rumaks
Juris Rumaks
IKIvars Kalvinsh
Ivars Kalvinsh
This review for the first time summarizes the data obtained in the neuropharmacological studies of mildronate, a drug previously known as a cardioprotective agent. In different animal models of neurotoxicity and neurodegenerative diseases, we demonstrated its neuroprotecting activity. By the use of immunohistochemical methods and Western blot analysis, as well as some selected behavioral tests, the new mechanisms of mildronate have been demonstrated: a regulatory effect on mitochondrial processes and on the expression of nerve cell proteins, which are involved in cell survival, functioning, and inflammation processes. Particular attention is paid to the capability of mildronate to stimulate learning and memory and to the expression of neuronal proteins involved in synaptic plasticity and adult neurogenesis. These properties can be useful in neurological practice to protect and treat neurological disorders, particularly those associated with neurodegeneration and a decline in cognitive functions.